QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nuwellis-receives-uspto-notice-of-patent-allowance-for-innovative-pediatric-crrt-technology

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid...

 nuwellis-announces-pricing-of-27m-public-offering-of-1125m-shares-of-common-stock-and-warrants-to-purchase-up-to-an-aggregate-of-16875m-shares-of-its-stock-at-a-combined-public-offering-price-024share

Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on transformin...

 nuwellis-has-received-a-notice-of-allowance-for-its-us-patent-application-18463612-titled-venous-blood-flow-stimulator-for-extracorporeal-therapy

https://patentcenter.uspto.gov/applications/18463612/ifw/docs 

 nuwellis-filed-us-patent-application-20240108533---venous-blood-flow-stimulator-for-extracorporeal-therapy

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240108533

 nuwellis-announced-results-from-two-new-clinical-data-analyses-from-the-avoid-hf-trial-demonstrating-benefits-of-aquadex-system-for-heart-failure

- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failur...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION